What is BioCentric?
Established in 2001, BioCentric operates at the intersection of science-centered communication and innovative digital solutions. The company provides a comprehensive suite of services designed to optimize the lifecycle of pharmaceutical products, ranging from early-stage clinical trial support to sophisticated patient activation initiatives. Beyond traditional consulting, BioCentric distinguishes itself through its proprietary Datagame platform, which integrates advanced analytics with gamified educational tools. This unique approach enhances health literacy for both patients and healthcare professionals, ensuring that complex medical data is translated into actionable insights that drive stakeholder value and improve clinical outcomes.
How much funding has BioCentric raised?
BioCentric has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in BioCentric
PPP
Public-Private Partnership
What's next for BioCentric?
With the successful completion of this late-stage financing, BioCentric is strategically positioned to scale its digital infrastructure and expand its footprint in the global pharmaceutical services market. The company is expected to prioritize the enhancement of its Datagame analytics capabilities, aiming to provide deeper, data-driven insights that address the evolving needs of government entities and multinational drug developers. As the life sciences industry continues to prioritize patient-centric engagement, BioCentric's focus on serious game development and medical affairs will likely serve as a critical differentiator, enabling the firm to capture additional market share while maintaining its reputation for high-impact, science-led communication strategies.
See full BioCentric company page
